Establishing a Long-term Treatment Plan for Patients With Schizophrenia: INVEGA TRINZA® (paliperidone palmitate) and INVEGA SUSTENNA® (paliperidone palmitate)

Saturday, October 27
12:15 PM - 1:30 PM
Location: W232

Non-CME. Lunch will be served. Seating is limited.
Uncover the latest information, data, and research findings with disease-state or product-specific presentations. Ask questions of key experts and industry representatives and assess the value to your patient care. Seating is limited and available on a first-come, first-served basis. Innovation Theater presentations are not intended or eligible for CME/CE credit.

Speaker(s)
Sanjai Rao, M.D.
Associate Clinical Professor of Psychiatry
Associate Residency Training Director
University of California, San Diego
Site Director, Residency Training
VA Medical Center, San Diego, CA

This presentation is provided by Janssen Pharmaceuticals, Inc.


Assets

Establishing a Long-term Treatment Plan for Patients With Schizophrenia: INVEGA TRINZA® (paliperidone palmitate) and INVEGA SUSTENNA® (paliperidone palmitate)



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Establishing a Long-term Treatment Plan for Patients With Schizophrenia: INVEGA TRINZA® (paliperidone palmitate) and INVEGA SUSTENNA® (paliperidone palmitate)